Orphacol
cholic acid
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Orphacol. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Orphacol.
For practical information about using Orphacol, patients should read the package leaflet or contact their doctor or pharmacist.
-
List item
Orphacol : EPAR - Summary for the public (PDF/85.95 KB)
First published: 02/10/2013
Last updated: 02/10/2013 -
-
List item
Orphacol : EPAR - Risk-management-plan summary (PDF/105.97 KB)
First published: 28/07/2021
Authorisation details
Product details | |
---|---|
Name |
Orphacol
|
Agency product number |
EMEA/H/C/001250
|
Active substance |
cholic acid
|
International non-proprietary name (INN) or common name |
cholic acid
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
A05AA03
|
Additional monitoring |
This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring. |
Exceptional circumstances |
This medicine was authorised under exceptional circumstances, because the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This can happen because the condition to be treated is rare or because collection of full information is not possible or is unethical. For more information, see Pre-authorisation guidance. |
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Laboratoires CTRS
|
Revision |
13
|
Date of issue of marketing authorisation valid throughout the European Union |
12/09/2013
|
Contact address |
16 Rue Montrosier |
Product information
15/05/2023 Orphacol - EMEA/H/C/001250 - IAIN/0052/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
Orphacol is indicated for the treatment of inborn errors in primary bile-acid synthesis due to 3β-hydroxy-Δ5-C27-steroid oxidoreductase deficiency or Δ4-3-oxosteroid-5β-reductase deficiency in infants, children and adolescents aged one month to 18 years and adults.